Shellie Fravel, PharmD

This is topic 1b not a 1B graded suggestion, because the data I'm seeing that this is a make believe problem. Further damning of iron by ESA pushers.

#ShowMeTheEvidence
#NephJC

Sliding in a little late! Shellie Fravel, pharmacist joining from iowa city. No COI. #nephjc

2026 KDIGO Anemia Management Guidelines — NephJC This week, we will discuss 2026 KDIGO anemia management in patients with kidney disease

#NephSky #MedSky
🩸Blood is thicker than water 🌊
Thankfully we thinned out the 2026 KDIGO Anemia Guidelines for you to peruse.
Come discuss what's new.
Tuesday 2/24/26 at 9pm EST on Bluesky!
Summary by @jeyakumarmeyyappan.bsky.social
www.nephjc.com/news/kdigo-anemia

KDIGO 2026 Anemia in CKD: The Visual Abstract — NephJC Anemia remains a central challenge in chronic kidney disease, influencing quality of life, cardiovascular risk, and clinical outcomes. The updated KDIGO 2026 guideline provides practical recommendatio...

Hey #MedSky #NephSky
KDIGO has updated their guidance on anemia in kidney disease for the first time in a decade! Let's discuss 2/24/26 at 9pm EST
Check out the VA by @shelliefravel.bsky.social
www.nephjc.com/news/2026/2/23/kdigo-2026-anemia-in-ckd

GFR Measured With Computerized Tomography Urography in Healthy Individuals and Patients With CKD Opportunistic computed tomography (CT)-based screening is the practice of exploiting incidental imaging data for prevention, risk profiling, or presymptomatic detection of relevant disease unrelated…

GFR Measured With Computerized Tomography Urography in Healthy Individuals and Patients With CKD

bit.ly/3XsLlQY #OpenAccess

Shellie Fravel, pharmacist joining from Iowa City, no COI #nephjc

Smartwatch and Hypertension Notification This cross-sectional study assesses the potential impact of a smartwatch hypertension notification feature for US adults who have not been diagnosed with hypertension.

Excited to share our research letter published today in JAMA on the new Apple Watch Hypertension Notification Feature! jamanetwork.com/journals/jam...

1/n

To INFINITI and Beyond: SGLT2 Inhibitors in Kidney Transplant Patients — NephJC This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.

Hey #NephSky
2/10/26 at 9 pm EST we'll discuss
#Flozinating into the Future & Beyond...
SGLT2i in kidney transplant recipients.
What's the latest evidence of risk/benefit?
Do #Flozins act mechanistically the same in de-innervated kidneys?
Come chat.
www.nephjc.com/news/inifinti-flozins-transplant

Why aren’t you prescribing fish oil to your dialysis patients? PISCES showed a striking cardiovascular benefit with fish oil in hemodialysis. Lovaza closely matches the trial’s ethyl-ester formulation, is FDA regulated, EHR friendly, and offers a practical, re…

PBFluids▶️PISCES showed a striking cardiovascular benefit with fish oil in hemodialysis. Lovaza closely matches the trial’s ethyl-ester formulation, is FDA regulated, EHR friendly, and offers a practical option while we wait for the exact formulation pbfluids.com/2026/01/why-...

Up next on #NephJC we will be unpacking SGLT2i in transplant recipients👇

journals.lww.com/cja...

Shellie Fravel, pharmacist signing on from Iowa City, no COI #nephjc

🍌🥑Can pushing K⁺ to the high-normal range reduce ICD shocks and hospitalizations?

🎨 #Visualabstract by @jeyakumarmeyyappan.bsky.social

⏰ #NephJC chat on Jan 27, 9 pm EST

www.nephjc.com/news/2026/1/...

POTCAST- K+ Pop and Arrhythmia Drop — NephJC This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.

Oh, the weather outside is frightful 🥶🥶
But #NephJC is so delightful,
and since you've no place to go #NephSky...
Come discuss POTCAST: potassium goals and cardiac arrhythmias 1/27/26 at 9pm EST on #Bluesky
Summary by @shelliefravel.bsky.social @salinesolut.bsky.social
www.nephjc.com/news/potcast

Sodium-Glucose Cotransporter-2 Inhibitors #SGLT2i and #Cardiorenal Events in #Nonalbuminuric Kidney Disease

#VisualAbstract by Augusto Cesar S Santos Jr

https://www.kireports.org/article/S2468-0249(25)00774-0/fulltext

@cwhuang0824

Can measuring glomerular filtration finally be easy? Assessment of glomerular filtration rate (GFR) has progressed through a series of practical trade-offs between physiological accuracy and clinical feasibility. Direct measurement of GFR using exogenou...

Can measuring glomerular filtration finally be easy?
#nephsky #nephrology
www.kireports.org/article/S246...

Top Stories in Nephrology 2025 — NephJC 2025 was rich in successful stories. Here are the top 10 that impressed our audience.

It's 2026!🎉
We will be counting down the Top Ten Nephrology Stories of 2025 on 1/6/26 at 9 pm EST.
Join us on TWITTER (it will always be Twitter to us).
Come on by #NephJC faithful for a lively discussion! You picked & we're count'em down.
www.nephjc.com/news/2025/1/3/top-stories-in-nephrology-2025

Did we (meaning "you" of course, because you voted) get them right? Is there something missing or is the order wrong? #NephJC #TopTenStories2025
Come discuss with an international cadre of nephrologists & other interested parties on 1/6/26 at 9 pm EST on #Twitter

The future of nephrology

1/10

Last #NephJC we discussed dialysis frequency in AKI-D #TenPostNephJC

We sought to answer an age-old question: Is less is really more? Or less is just simply what it is….less?

pubmed.ncbi.nlm.nih.gov/41201895/

The debate about kidney function estimation in cancer patients is not over. What is important to remember is that mCrCl is not mGFR

Less dialysis is…less dialysis. #NephJC
Sure I’d like to see faster recovery and lower mortality. But what if conservative strategy is only “non-inferior”. Is that good enough, especially if dialysis is a limited resource like @nephroseeker.bsky.social says

Dialyze Less, Recover More? AKI’s Chance to Get LIBERATE-D — NephJC This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.

Join us for the last #NephJC of 2025, 12/16/25 at 9pm EST!🥳
How soon should we withhold dialysis in AKI?
We're discussing the LIBERATE-D trial #NephSky
This one might just change your mind 🧠🧠
Blog by @msocomd.bsky.social and @sejalplakhani.bsky.social
www.nephjc.com/news/liberated-aki

LIBERATE-D: The Visual Abstract — NephJC In patients with dialysis-dependent acute kidney injury, a conservative dialysis strategy was evaluated in the LIBERATE-D trial. Could less be more? Join the discussion in #NephJC, but first, check ou...

The LIBERATE-D VA by
@sejalplakhani.bsky.social

Should we break the pattern of thrice weekly dialysis in AKI-D? #NephJC #NephSky

www.nephjc.com/news/liberateva

VA of SPARK trial

Our take on the baxdrostat PA trial in @asnpublications.bsky.social #KidneyNews

www.kidneynews.org/view/journal... with @nephroseeker.medsky.social and @dramiliflores.bsky.social !

Thanks to Sam Kant and @kdjhaveri.bsky.social for the invite!!

Agree!

Yes so…

-Lovaza 3 capsules 1395 EPA / 1125 DHA
-Lovaza 4 capsules 1860 EPA / 1500 DHA

vs

-Study 4 capsules 1600 EPA / 800 DHA

I guess the question is if either regimen is close enough to presume equal benefit/safety?

Have you tried prescribing generic Lovaza? I think that it’s a close match to the EPA/DHA content in the trial if you order 2 capsules BID.

I think Lovaza is close. Each 1g capsule contains 465 mg EPA and 375 mg DHA and is dosed as 4 capsules a day for high TG. It is also available generic now so reasonably priced. #NephJC www.costplusdrugs.com/medications/...

Shellie Fravel joining from Iowa City. No COI. #NephJC

Fish Oil in Dialysis: A Big Catch or an Empty Net — NephJC Holy Mackerel! This week we will discuss fish oil use in maintenance hemodialysis patients. Could this be the one thing that bends the curve on CV mortality, or is it just a red herring?

Maybe the most shocking study from #KidneyWk.
🐚From the depths of the oceans to #BlueSky, we're discussing PISCES 🐟 12/2/25 9pm EST. #NephJC
Are you hooked🪝on fish oil for CV disease in ESRD, or are you throwing it back 🌊?
www.nephjc.com/news/pisces-fishoil